Switch theme
Sign up to access all valuation multiples
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
2023
57
LTM Revenue n/a
LTM EBITDA -$84.6M
$15.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
enGene has a last 12-month revenue of n/a and a last 12-month EBITDA of -$84.6M.
In the most recent fiscal year, enGene achieved revenue of n/a and an EBITDA of -$52.0M.
enGene expects next 12-month revenue of XXX and NTM EBITDA of XXX
See enGene valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$94.8M | -$52.0M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$24.5M | -$99.9M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Debt | $11.7M | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, enGene's stock price is $4.
enGene has current market cap of $204M, and EV of $15.2M.
See enGene trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $15.2M | $204M | XXX | XXX | XXX | XXX | $-1.71 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, enGene has market cap of $204M and EV of $15.2M.
enGene's trades at n/a LTM EV/Revenue multiple, and -0.2x LTM EBITDA.
Analysts estimate enGene's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for enGene and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $15.2M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -0.2x | XXX | XXX | XXX |
| P/E | -3.2x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpenGene's NTM/LTM revenue growth is n/a
enGene's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.1M for the same period.
Over next 12 months, enGene's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate enGene's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for enGene and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | -45% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
enGene acquired XXX companies to date.
Last acquisition by enGene was XXXXXXXX, XXXXX XXXXX XXXXXX . enGene acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was enGene founded? | enGene was founded in 2023. |
| Where is enGene headquartered? | enGene is headquartered in United States of America. |
| How many employees does enGene have? | As of today, enGene has 57 employees. |
| Who is the CEO of enGene? | enGene's CEO is Mr. Ronald H.W. Cooper. |
| Is enGene publicy listed? | Yes, enGene is a public company listed on NAS. |
| What is the stock symbol of enGene? | enGene trades under ENGN ticker. |
| When did enGene go public? | enGene went public in 2023. |
| Who are competitors of enGene? | Similar companies to enGene include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of enGene? | enGene's current market cap is $204M |
| What is the current EBITDA of enGene? | enGene's last 12-month EBITDA is -$84.6M. |
| What is the current EV/EBITDA multiple of enGene? | Current EBITDA multiple of enGene is -0.2x. |
| Is enGene profitable? | Yes, enGene is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
